Background: Vaccination against COVID-19 continues apace, but side-effects, both common and severe, continue to be reported. We report here the first published case of COVID-19 vaccine-related encephalitis.
Case Presentation: A young woman presented with acute neuropsychiatric symptoms following recent ChAdOx1 nCoV-19 vaccination. Extensive investigation did not identify alternative causes.
Conclusions: This difficult case is here described, including presentation, investigation, and management. Further study on neuropsychiatric side-effects of COVID-19 vaccination, including investigation as to whether there may be a causal link, is required.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666465 | PMC |
| http://dx.doi.org/10.1186/s12883-021-02517-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of COVID-19 Vaccines in Patients With Multiple Sclerosis: A Cross-Sectional Study From a Tertiary Rehabilitation Center in Saudi Arabia.
Cureus
December 2024
Internal Medicine, Sultan Bin Abdulaziz Humanitarian City, Riyadh, SAU.
Background The safety and adverse effects (AEs) associated with approved COVID-19 vaccines in individuals with multiple sclerosis (MS) require further examination, particularly as there is limited information available for MS patients in Saudi Arabia. This study sought to investigate the reported AEs of COVID-19 vaccines among MS patients admitted to a major rehabilitation center in Saudi Arabia. Methods A cross-sectional analysis was conducted from January 2023 to March 2024 at Sultan Bin Abdulaziz Humanitarian City (SBAHC) in Riyadh.
View Article and Find Full Text PDFSerological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.
Sci Rep
January 2025
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT, UK.
During the COVID-19 pandemic, heterologous vaccination strategies were employed to alleviate the strain on vaccine supplies. The Thailand Ministry of Health adopted these strategies using vector, inactivated, and mRNA vaccines. However, this approach has introduced challenges for SARS-CoV-2 sero-epidemiology studies.
View Article and Find Full Text PDFImmunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort.
Vaccines (Basel)
December 2024
Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES/EBSERH), Vitória 29041-295, ES, Brazil.
Background/objectives: The effectiveness of COVID-19 vaccine in patients with immune-mediated inflammatory diseases (IMID) depends on the underlying disease, immunosuppression degree and the vaccine regimens. We evaluate the safety and immunogenicity of different COVID-19 vaccine schedules.
Methods: The SAFER study: "Safety and effectiveness of the COVID-19 Vaccine in Rheumatic Disease", is a Brazilian multicentric prospective observational phase IV study in the real-life.
Post ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) (Covishield) Brachial Plexitis - Report of Two Cases Along with Review of Literature.
Neurol India
November 2024
Consultant Radiologist, Getwell Polyclinic and Research Center, Jaipur, Rajasthan, India.
Various neurological complications have been linked with vaccines ranging from encephalitis, stroke, ADEM to GBS and many more. Although both viral as well as bacterial vaccines have been reported to cause neurological adverse events, brachial plexitis following vaccination is very uncommon. Vaccination drive against COVID-19 was started on 16th Jan 2021 in India.
View Article and Find Full Text PDFPredictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Vaccine
December 2024
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Institute of Global Health, University of Siena, Siena, Brazil. Electronic address:
Objectives: To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes.
Methods: A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!